Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Gustave Roussy Remains the No. 1 Cancer Centre in France and Europe
The excellence of Gustave Roussy has once again been recognised by the American magazine Newsweek, which has ranked the Institute as the leading cancer centre in France and in Europe, and among the very best worldwide, following the publication of the World’s Best Specialised Hospitals 2026 ranking.
Published on
The excellence of Gustave Roussy has once again been recognised by the American magazine Newsweek, which has ranked the Institute as the leading cancer centre in France and in Europe, and among the very best worldwide, following the publication of the World’s Best Specialised Hospitals 2026 ranking.
Published annually by Newsweek in collaboration with Statista, the World’s Best Specialised Hospitals 2026 ranking is based on the results of an online survey of tens of thousands of healthcare experts worldwide and takes into account quality indicators reported by patients.
“This ranking highlights France’s ability to shine on the scientific stage. Gustave Roussy secures its place in the world’s Top 10, at sixth position, competing with centres with vastly larger budgets, thereby demonstrating the Institute’s capacity for innovation and the talent of its teams. This result, which is a source of pride for all our staff, is also a call to strengthen public and private investment so that French research can compete with the leading American and Asian oncology centres,” says Professor Fabrice Barlesi, Chief Executive Officer of Gustave Roussy.
In this context of heightened global competition with institutions that enjoy budgets far exceeding those available in France and unparalleled human resources, Gustave Roussy’s continued presence in the world’s Top 10 – ranking first in France and first in Europe – is an exceptional achievement. It is evidence of the innovative strength and talent of French teams and of the unwavering commitment of the Institute’s staff to deliver the highest quality of care to all patients, alongside top-level research with major societal impact. Researchers and clinicians continue to work towards their goal of curing 80 % of patients with cancer by 2040.
Last news
-
ADCs: Two Landmark Publications in Cancer Cell and Nature Medicine Showcase Gustave Roussy's Expertise
In less than two months, researchers and clinicians from Gustave Roussy have contributed to two major publications on Antibody-Drug Conjugates (ADCs) in Cancer Cell and Nature Medicine. Together, these papers provide both a comprehensive overview of current knowledge and a strategic vision to accelerate the development of the next generation of these innovative therapies.
-
Drug shortages: Gustave Roussy becomes the only Cancer Centre in France authorised to produce Special Hospital Preparations
The Clinical Pharmacy Department at Gustave Roussy has been authorised by the French Ministry of Health to manufacture Special Hospital Preparations (SHPs). Granted for a period of seven years, this accreditation enables the Institute’s hospital pharmacy to produce certain medicines in coordination with the French National Agency for the Safety of Medicines and Health Products (ANSM) and the Ministry of Health. Gustave Roussy is the only French Comprehensive Cancer Centre (CLCC) authorised to manufacture Special Hospital Preparations, alongside ten university hospitals.
-
Personalising Breast Cancer Treatments: 5 Questions with Dr Barbara Pistilli
Advances in treatment and patient care mean that five-year net survival for breast cancer now reaches 88%1 in France. However, with around 60,000 new cases diagnosed each year in France alone, breast cancer remains a major public health challenge. One reason is the side effects associated with treatment. In response to this issue, Dr Barbara Pistilli, Head of the Breast Cancer Committee at Gustave Roussy, advocates an approach centred on personalised care, ensuring that each woman receives a treatment intensity tailored to her tumour and individual journey, without compromising her chances of recovery.
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
